Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia
نویسندگان
چکیده
منابع مشابه
Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.
A cell-line derived from a patient with chronic myelogenous leukemia (CML) is described. The new cell-line, which has over 175 serial passanges in a 3 1/2-yr period, has the following characteristics: (1) CML cells started to proliferate actively since they were first incubated in culture media. A threefold increase in the total number of cells was observed during the first seven passages; the ...
متن کاملPhiladelphia chromosome-negative, bcr/abl-positive chronic myelogenous leukemia.
Chronic myelogenous leukemia(CML)is characterized by the presence of the abnormal chromosome 22, which is termed the Philadelphia chromosome(Ph). The Ph is derived from a translocation between chromosomes 9 and 22, t (9; 22)(q 34; q 11). The c-abl oncogene on the long arm of chromosome 9 fused to the bcr gene on the long arm of chromosome 22 and leads to the formation of a chimeric bcr abl gene...
متن کاملTreatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
PURPOSE Imatinib mesylate, a specific Bcr-Abl tyrosine kinase inhibitor, has shown encouraging activity in chronic myelogenous leukemia (CML). EXPERIMENTAL DESIGN We treated 237 patients (median age, 50 years; age range, 18-82 years) with Philadelphia chromosome (Ph)-positive accelerated-phase CML with oral imatinib mesylate at daily doses of 400 mg (26 patients) or 600 mg (211 patients) and ...
متن کاملImatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
BACKGROUND AND OBJECTIVES Imatinib mesylate (STI571) is a selective inhibitor of the bcr/abl tyrosine kinase with therapeutic potential in the blast crisis (BC) of chronic myelogenous leukemia (CML). DESIGN AND METHODS We report the characteristics and clinical outcome of 30 patients [16 males and 14 females, median age 50 (range, 18 to 72) years] with CML in BC included in a phase II interna...
متن کاملOutcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
BACKGROUND The prognosis of patients with chronic myelogenous leukemia (CML) after failure of imatinib mesylate therapy is not well documented. METHODS The outcome of 420 patients with CML post-imatinib failure (resistance-recurrence in 374; toxicities in 46) were reviewed in relation to survival, overall, and by different therapies. RESULTS The estimated 3-year survival rates were 72% in 8...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer
سال: 1997
ISSN: 0008-543X,1097-0142
DOI: 10.1002/(sici)1097-0142(19970801)80:3<396::aid-cncr7>3.0.co;2-q